New systemic frontline treatment for metastatic colorectal carcinoma
Ada Braun(Amgen (United States)), P. Preusser(University Hospital Münster), W. Achterrath(Messer (Germany)), H. Wilke(Kliniken Essen-Mitte), U. Vanhoefer, A. Harstrick(Merck KGaA, Darmstadt (Germany))
Cited by 71
Related Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|Journal of Clinical Oncology|2005|491
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
|Journal of Clinical Oncology|2003|259
Denosumab for Treatment of Hypercalcemia of Malignancy
|The Journal of Clinical Endocrinology & Metabolism|2014|200